Board Member Lens

Governance dashboard

What the board sees when it logs in. Q-over-Q financials, top risks, decisions awaiting input, and succession-plan readiness — all sourced to Verdant Harbor’s operating reality.

Q-over-Q financials snapshot · FY2025

Total revenue

$6,240,000

Internally consistent across all lenses

Total expenses

$6,055,000

77.9% program services

Net assets

$1,810,000

Reserves position

Operating margin

3.0%

Within board policy band

Top 3 risks this cycle

Risk 1 · high

Due 2026-05-08

SAMHSA Block Grant Q1 narrative report due May 8

Required quarterly programmatic narrative for the SAMHSA Community Mental Health Block Grant ($1.09M/yr). Template requires narratives on three workforce outcomes, two equity indicators, and beneficiary demographics. Last year’s submission triggered two follow-up questions from the program officer; current draft has not addressed those.

Surfaced by: Compliance engine

Risk 2 · high

Due 2026-06-30

Ryan White Part C subrecipient compliance report due June 30

Verdant operates as a Part C subrecipient ($420K subgrant) supporting HIV Care Continuum + PrEP Navigation. Mid-year compliance package due to the primary recipient includes: viral-suppression rates, retention-in-care percentages, payer-of-last-resort attestation, and the sub-recipient pass-through to Forge Hollow Outreach ($44K). Last cycle the primary recipient flagged a gap between case-management notes and the reported retention number; the gap was reconciled but the corrective action plan has not yet been documented in this cycle’s package.

Surfaced by: Compliance engine

Risk 3 · medium

Due 2026-05-31

Laboratory testing vendor contract renewal

Current vendor provides urine drug screening for the MAT program at $28 per screen, 2,400 screens annually. Vendor notified 90-day renewal window; renewal rate proposed at $34/screen (+21%). Regional competitor quote available at $29/screen with 60-day transition runway. Margin impact on MAT program meaningful.

Surfaced by: Revenue engine

Decisions awaiting board input

Recovery program care coordination budget escalation

Surface the request at the May board meeting with a funding path from the program-specific foundation grant renewal ($180K pending).

May 14 board meeting — Q1 financials and strategic review

Surface the three strategic items as a single "Growth Levers" page in the board deck; frame each with the relevant financial or operational data already in the financials section.

Succession plan readiness

Executive Director

Dr. Amara Okafor

Executive Director · since 2019

Interim coverage documented · 90-day plan on file

Chief Financial Officer

Marcus Reinhart

Chief Financial Officer · since 2021

Interim coverage documented

Chief Clinical Officer

Dr. Priya Chen

Chief Clinical Officer · since 2020

Cross-coverage with Outpatient Director documented

Governance composition score: 71/100 · Board count: 8